Deutsche Bank AG Increases Stake in Alphatec Holdings, Inc. $ATEC

Key Points

• Deutsche Bank AG increased its stake in Alphatec Holdings by 11.8% in Q1, owning approximately 0.81% of the company worth $12 million after acquiring additional shares.
• Alphatec's stock received several positive ratings from analysts, with targets ranging from $15.00 to $22.00, leading to a consensus rating of "Buy".
• Insider activity includes significant share sales, with 449,997 shares sold over the past 90 days, representing 20.90% of the stock currently owned by insiders.

Deutsche Bank AG boosted its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 11.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,185,235 shares of the medical technology company's stock after purchasing an additional 124,785 shares during the quarter. Deutsche Bank AG owned about 0.81% of Alphatec worth $12,018,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Lido Advisors LLC grew its position in Alphatec by 8.4% during the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after purchasing an additional 953 shares during the last quarter. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company's stock valued at $100,000 after acquiring an additional 1,342 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Alphatec by 13.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after acquiring an additional 1,552 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in shares of Alphatec by 0.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 288,967 shares of the medical technology company's stock valued at $2,653,000 after acquiring an additional 1,784 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Alphatec news, COO Scott Lish sold 9,302 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $16.00, for a total transaction of $148,832.00. Following the sale, the chief operating officer owned 665,030 shares in the company, valued at approximately $10,640,480. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total transaction of $269,751.72. Following the sale, the general counsel owned 438,331 shares in the company, valued at approximately $6,535,515.21. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 403,924 shares of company stock worth $5,275,573. Company insiders own 22.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a report on Monday, June 16th. Barclays reaffirmed an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price target on shares of Alphatec in a report on Friday, May 2nd. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Alphatec currently has an average rating of "Buy" and an average target price of $18.50.

Alphatec Stock Performance

Shares of NASDAQ:ATEC traded down $0.08 during trading on Tuesday, hitting $15.78. The company's stock had a trading volume of 207,864 shares, compared to its average volume of 2,061,450. The company has a 50-day moving average of $12.02 and a 200-day moving average of $11.45. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $16.01. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -13.94 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The company had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. During the same quarter last year, the business earned ($0.29) EPS. The firm's revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.